Tower Research Capital (TRC)’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-838
Closed -$19K – 6042
2020
Q4
$19K Sell
838
-8,630
-91% -$109K ﹤0.01% 3920
2020
Q3
$96K Buy
9,468
+5,241
+124% +$70.3K ﹤0.01% 3180
2020
Q2
$63K Buy
4,227
+2,874
+212% +$44.3K ﹤0.01% 2877
2020
Q1
$16K Sell
1,353
-2,853
-68% -$45.4K ﹤0.01% 1833
2019
Q4
$67K Buy
+4,206
New +$53.6K 0.01% 1161
2019
Q3
– Sell
-614
Closed -$8K – 4753
2019
Q2
$8K Buy
+614
New +$8.95K ﹤0.01% 2732

Tower Research Capital (TRC)'s PRVL Position: Q1 2021 in Review

Tower Research Capital (TRC) sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 838 shares — an estimated $19K sold.

Tower Research Capital (TRC) first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $96K in Q3 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Tower Research Capital (TRC) reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 838 Prevail Therapeutics shares in Q1 2021, an estimated $19K.
  • Tower Research Capital (TRC) first reported a position in Prevail Therapeutics in Q2 2019 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Prevail Therapeutics position peaked at $96K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2021, filed 17 May 2021.